Numoda is currently managing Columbia’s ongoing Pregnant study of Prochieve 8% (progesterone gel) to reduce the risk of preterm birth in women with a short cervix at mid-pregnancy.
Robert Mills, Columbia’s president and CEO, said: “We are pleased to receive this support and vote of confidence in our company. We welcome the interest and investment by Numoda in Columbia’s future.”
Mary Schaheen, Numoda’s CEO, said: “If the Pregnant study is successful, it could lead to improved care for a large number of women at risk for preterm birth and better outcomes for their babies. Numoda is excited to participate in the study and in this investment.”